PODCAST
Reducing Fill Risk in Drug Product Manufacture Utilizing New State-of-the-Art Systems and Platforms

PODCAST
The Challenge of Staying Current with Regulatory Changes – How one company is providing a solution

WuXi Biologics Signs Lease for a Clinical Manufacturing Facility
in the United States

WuXi Biologics Closes Land Deal to Build State-of-the-Art Biologics Production Facility in Worcester, MA

WuXi Biologics Completed Acquisition
of a Drug Product Manufacturing Facility in Germany

WuXi Biologics (Suzhou) Successfully Passed First
EMA GMP Inspection

WuXi Biologics Successfully Completes PFS Filling at its Robotic Aseptic Filling Facility
WuXi Biologics standardizes a remarkable 12 month “DNA to IND” timeline through its streamlined development platform
WuXi Biologics and Aravive Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

WuXi Biologics & Vir Biotechnology Announce Collaboration for
Global Development of Antibodies
to Treat COVID-19

WuXi Biologics Congratulates Immutep on Positive Interim data for IMP-321
WuXi Biologics Records
Excellent Interim Results
WuXi Biologics’ Regulatory Affairs team provides a quarterly summary of regulatory updates organized by agency and by topic. These updates support your efforts to stay current in our ever-changing regulatory environment.
WuXi Biologics Awarded as
“Most Honored Company”
by Institutional Investor

WuXi Biologics Sweeps 2020 CMO Leadership Awards in All Six Categories
To read more about WuXi Biologics visit our Newsletter Archive